MedPath

on interventionel prospective study to develop a prognostic scoring system for outcome of autologous transplantation in multiple myeloma (MM).

Recruiting
Conditions
C90
Multiple myeloma and malignant plasma cell neoplasms
Registration Number
DRKS00003964
Lead Sponsor
niversitätsklinikum Freiburg
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

MM-patients.

Exclusion Criteria

none

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The aim o the study is to prospectively validate a prognostic scoring sytem for<br>outcomes (EFS,OS) of autologous transplantation in Multiple Myeloma, developed<br>retrospectively at Hammersmith Hospital, London, based on tumour load at<br>diagnosis (Plasmacell% on trephine),cytogenetic aberrations (FISH and metaphase<br>cytogenetics) and treatment responses to chemotherapy prior to autologous<br>transplant.
Secondary Outcome Measures
NameTimeMethod
Test the predictive power of the score to identify a subgroup of high risk patients<br>who currently profit least from autologous stem cell transplantion and may be<br>candidates for therapeutic trials of novel agents.<br>Develop the prognostic score as a tool for such risk adapted therapies.<br>Validate the scoring sytem in patients treated with novel agents/drug combinations<br>Further definition of cytogenetic risk groups
© Copyright 2025. All Rights Reserved by MedPath